179 related articles for article (PubMed ID: 30073931)
1. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
[TBL] [Abstract][Full Text] [Related]
2. Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia.
Hagag AA; Badraia IM; El-Shehaby WA; Mabrouk MM
J Oncol Pharm Pract; 2020 Sep; 26(6):1397-1406. PubMed ID: 31964219
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
6. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
[TBL] [Abstract][Full Text] [Related]
7. Modelling cardiac mechanics in doxorubicin-induced cardiotoxicity following childhood acute lymphoblastic leukemia using a combination of cardiac magnetic resonance imaging, cardiopulmonary exercise testing and the CircAdapt model.
Artz T; Caru M; Curnier D; Abasq M; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Biomech; 2023 Jun; 154():111616. PubMed ID: 37207545
[TBL] [Abstract][Full Text] [Related]
8. Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia.
El Amrousy D; El-Afify D; Khedr R; Ibrahim AM
Pediatr Blood Cancer; 2022 Jul; 69(7):e29496. PubMed ID: 34842343
[TBL] [Abstract][Full Text] [Related]
9. Detection of early anthracycline-induced cardiotoxicity in childhood cancer with dobutamine stress echocardiography.
Lenk MK; Zeybek C; Okutan V; Ozcan O; Gökçay E
Turk J Pediatr; 1998; 40(3):373-83. PubMed ID: 9763901
[TBL] [Abstract][Full Text] [Related]
10. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.
El-Shitany NA; Tolba OA; El-Shanshory MR; El-Hawary EE
J Card Fail; 2012 Aug; 18(8):607-13. PubMed ID: 22858075
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of taurine against doxorubicin-induced cardiotoxicity in rats: echocardiographical and histological findings.
Barış VÖ; Gedikli E; Yersal N; Müftüoğlu S; Erdem A
Amino Acids; 2019 Nov; 51(10-12):1649-1655. PubMed ID: 31673792
[TBL] [Abstract][Full Text] [Related]
13. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
14. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
Paiva MG; Petrilli AS; Moisés VA; Macedo CR; Tanaka C; Campos O
Pediatr Blood Cancer; 2005 Dec; 45(7):902-8. PubMed ID: 16035077
[TBL] [Abstract][Full Text] [Related]
16. Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
Liu G; Liu Y; Wang R; Hou T; Chen C; Zheng S; Dong Z
Cardiovasc Ther; 2016 Aug; 34(4):216-24. PubMed ID: 27097055
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Lapointe MO; Caru M; Curnier D; Raboisson MJ; Andelfinger G; Krajinovic M; Laverdière C; Sinnett D; Périé D
J Pediatr Hematol Oncol; 2023 Mar; 45(2):70-77. PubMed ID: 36161876
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
19. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
[TBL] [Abstract][Full Text] [Related]
20. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
